Fundraising Fox
Aptevo Therapeutics
NASDAQ: APVOSeattle, US · Delaware corporation · 2 known investors
Find your way into Aptevo Therapeutics
Sign up to see every warm intro you have to Aptevo Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Aptevo Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Aptevo Therapeutics is a clinical-stage biotechnology company developing bispecific and trispecific immunotherapies to treat cancer. Its work focuses on improving treatment outcomes for cancer patients.
Founders & leadership
DT
Daphne TaylorExecutive
JG
Jeffrey G. LamotheExecutive Vice President and Chief Operating Officer
Board
JE
John E NiederhuberBoard director
DJ
Daniel J Abdun-NabiBoard director
GG
Grady Grant IIIBoard director
ZH
Zsolt HarsanyiBoard director
BL
Barbara Lopez KunzBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$5.6M disclosed across 2 of 3 rounds · 2025–2026
▶$3.5MraisedAug 2026 · 3 investors · PharmaceuticalsRule 506(c)
▶$3.5MraisedAug 2026 · 3 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Jeffrey G LamotheExecutive Officer, Director
- Marvin L WhiteExecutive Officer, Director
- Daphne TaylorExecutive Officer
- John E NiederhuberDirector
- Daniel J Abdun-NabiDirector
- Grady Grant IIIDirector
- Zsolt HarsanyiDirector
- Barbara Lopez KunzDirector
- Offering amount
- $3.5M
- Amount sold
- $3.5M
- Sales commissions
- $315K
- Placement agents
- Roth Capital Partners, LLC
- First sale
- Aug 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$2.1MraisedApr 2025 · 11 investors · PharmaceuticalsRule 506(c)
▶$2.1MraisedApr 2025 · 11 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Marvin L WhiteExecutive Officer, Director
- Offering amount
- $2.1M
- Amount sold
- $2.1M
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Aptevo Therapeutics do?
- Aptevo Therapeutics is a clinical-stage biotechnology company developing bispecific and trispecific immunotherapies to treat cancer. Its work focuses on improving treatment outcomes for cancer patients.
- Who are Aptevo Therapeutics's investors?
- Aptevo Therapeutics's investors include HEALTHCARE ROYALTY PARTNERS, Yorkville Advisors.
- How much funding has Aptevo Therapeutics raised?
- Aptevo Therapeutics has disclosed $5.6M raised across 2 of its 3 known rounds.
- Where is Aptevo Therapeutics headquartered?
- Aptevo Therapeutics is headquartered in Seattle, US.